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CardiovascularModerate weight loss (>5%), which has been associated with improvements in glycemic parameters in
patients with dysglycemia, also reduces the presence of other comorbidities, including dyslipidemia and
hypertension, culminating in a reduced risk of cardiovascular disease. Lifestyle changes are the recommended
preliminary approach to weight loss, with an initial weight-loss goal of 10% of body weight achieved over 6
months at a rate of 1–2 pounds per week selected as an appropriate target to decrease the severity of obesity-
related risk factors. Implementing and maintaining the lifestyle changes associated with weight loss can,
however, be challenging for many patients. Therefore, additional interventions sometimes may be necessary.
Bariatric surgery can also be a highly effective option for weight loss and comorbidity reduction, but surgery
carries considerable risks and is still applicable only to selected patients with type 2 diabetes. Thus, attention
is turning to the use of weight-loss medications, including 2 recently approved compounds: twice-daily
lorcaserin and a once-daily combination of phentermine and topiramate extended-release, both shown to be
safe and effective therapies in the management of obesity in patients with type 2 diabetes.. Dr Garvey has served as an
stockholder of VIVUS, Inc. Dr
ry).
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Overweight and obesity are global epidemics affecting about 70%
and 35% of the US population, respectively (Flegal, Carroll, Kit, &
Ogden, 2012). Both are associated with type 2 diabetes mellitus
(T2DM), which itself increases the risk of weight gain (Flegal et al.,
2012; Reaven, 2003; Siram, Yanagisawa, & Skamagas, 2010; Tzotzas,
Evangelou, & Kiortsis, 2011). Type 2 diabetes mellitus and over-
weight/obesity both increase risk of cardiovascular disease (CVD) and
other comorbidities (American Diabetes Association, 2012; National
Heart, Lung, & Blood Institute. The Clinical Guidelines on the
Identiﬁcation, 1998). The American Diabetes Association (ADA)
suggests that management of T2DM in overweight/obese patients
should focus on control of hyperglycemia (HbA1c goal b7%) via
antidiabetic pharmacotherapy, together with moderate weight loss
(~7%) (American Diabetes Association, 2012), since the latter is
associated with improvements in glycemic parameters in patientswith dysglycemia and may subsequently reduce the need for
antidiabetic medications (American Diabetes Association, 2012).
While lifestyle changes (dietary modiﬁcation focused on caloric
reduction, increased physical activity, and behavior therapy)
(National Heart, Lung, & Blood Institute. The Clinical Guidelines on
the Identiﬁcation, 1998) can produce weight loss in overweight and
obese individuals, sustained adherence to these changes and
maintenance of weight reduction is often challenging (Greenberg,
Stampfer, Schwarzfuchs, Shai, & DIRECT Group, 2009; Mata, Todd, &
Lippke, 2010). This review will discuss T2DM and its comorbidities as
they relate to obesity and the need for treatment options to address
the associated risks. Two compounds that were recently approved by
the US Food and Drug Administration (FDA) for the chronic
management of obesity or overweight in the presence of ≥1
weight-related comorbidity as adjuncts to a reduced-calorie diet
and increased physical activity will be described: twice-daily (BID)
lorcaserin (BELVIQ 2012), and once-daily (QD) phentermine and
extended-release topiramate (PHEN/TPM ER) (QSYMIA 2012).
2. Obesity-related complications of type 2 diabetes
2.1. Pathophysiology of obesity and T2DM
Although obesity is fundamentally related to an imbalance between
energy intake and energy expenditure, it is estimated that genetic
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a population (de Ferranti & Mozaffarian, 2008; Lyon & Hirschhorn,
2005) via impact on hormone levels, body composition, and energy
metabolism (Lentes et al., 1999). Additional factors leading to
alterations in metabolism and/or appetite, such as a lack of sleep,
illness, and choice of macronutrients, can also contribute (de Ferranti &
Mozaffarian, 2008). The resultant energy imbalance leads to hypertro-
phy and hyperplasia of adipocytes (de Ferranti & Mozaffarian, 2008).
Adipose tissues modulate metabolism by releasing non-esteriﬁed fatty
acids (NEFAs), glycerol, hormones (e.g., leptin and adiponectin) (Lara-
Castro, Fu, Chung, & Garvey, 2007), and proinﬂammatory cytokines
(such as interleukin [IL]-6, and insulin growth factor [IGF]-1) (de
Ferranti&Mozaffarian, 2008; Kahn,Hull, &Utzschneider, 2006; Scherer,
2006; Shoelson, Lee, & Goldﬁne, 2006; Wellen & Hotamisligil, 2005).
The expansion of adipose tissue in obese patients is associated with
changes in the release of numerous adipokines from adipocytes, as well
as from macrophages and other cells that populate adipose tissue.
In particular, NEFAs, which are released from adipocytes, have
been shown to induce insulin resistance and impair β-cell function,
with increased levels observed in both obesity and T2DM (Boden,
1997; Kahn et al., 2006; Reaven, Hollenbeck, Jeng, Wu, & Chen, 1988).
Insulin resistance has also been shown to arise in healthy subjects in
response to high plasma NEFA levels induced through diet (Roden
et al., 1996), suggesting an association between insulin resistance and
obesity (Kahn et al., 2006). A possible mechanism for the β-cell
dysfunction associated with obesity (Kahn et al., 2006) that may also
contribute to the pathogenesis of T2DM (Schaffer, 2003) is lipid
(triglyceride) accumulation in pancreatic β-cells (de Ferranti &
Mozaffarian, 2008). In addition, the secretion of an adipokine,
adiponectin, which is associated with positive metabolic and vascular
effects, is reduced in obesity and may contribute to the pathogenesis
of metabolic syndrome, T2DM, and atherosclerosis (Lara-Castro et al.,
2007). Finally, it has been suggested that proinﬂammatory cytokines,
such as TNF-α secreted by macrophages present in adipose tissue,
play a signiﬁcant role in obesity-related insulin resistance (Kern,
Ranganathan, Li, Wood, & Ranganathan, 2001).2.2. Comorbidities of T2DM and obesity
The association between obesity and cardiometabolic risk factors,
such as dyslipidemia and hypertension (National Heart, Lung, & Blood
Institute. The Clinical Guidelines on the Identiﬁcation, 1998), may lead
to further complications in patients with T2DM (American Diabetes
Association, 2012; Eckel et al., 2011). For example, it has been
reported that even newly diagnosed T2DM is associated with a 25%
increase in risk of CVD, emanating from numerous contributorsFig. 1. Reductions in mortality by reduction in systolic blood pressure (SBP) (Choban(Wilson & Kannel, 2002). Since obesity often precedes the develop-
ment of T2DM, common pathogenic mechanisms (Eckel et al., 2011)
and comorbidities may already be present (National Heart, Lung, &
Blood Institute. The Clinical Guidelines on the Identiﬁcation, 1998;
Wilson & Kannel, 2002).
Obese patients with T2DM have been reported to show signiﬁ-
cantly increased serum levels of total cholesterol, low-density
lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL)
cholesterol, and triglycerides and decreased high-density lipoprotein
(HDL) cholesterol compared with non-obese patients with T2DM
(Saxena, Agrawal, Gautam, Bid, & Banerjee, 2009). Research in
monozygotic twins has shown that acquired obesity is associated
with increased activity of ﬁbrinogen and coagulation markers, which
are strongly correlated with inﬂammation and insulin resistance and,
as such, may increase risk of thrombosis and cardiovascular events
(Kaye et al., 2012).
Hypertension is also commonly seen with both T2DM and obesity
and is a major risk factor for CVD and microvascular complications.
Due to the synergistic effects of hypertension and T2DM, the
diagnostic cutoff for hypertension is lower for those with concurrent
T2DM (≥130/80 mm Hg) vs those without (≥140/90 mm Hg)
(American Diabetes Association, 2012; Chobanian et al., 2003).3. Effects of intentional weight loss on T2DM
Studies have shown that moderate weight loss in obese patients
with T2DM leads to decreased insulin resistance, improvements in
glycemic parameters, and reductions in T2DM-related complications
as well as in several CVD risk factors, including dyslipidemia and
elevated blood pressure (BP) (American Diabetes Association, 2012;
National Heart, Lung, & Blood Institute. The Clinical Guidelines on the
Identiﬁcation, 1998). Even modest reductions in risk factors can have
a substantial impact on mortality – for example, reductions in systolic
BP (SBP) of 5 mm Hg can reduce the risk of mortality from stroke by
14% and coronary heart disease (CHD) by 9% (Fig. 1) (Whelton
et al., 2002). In this article, we discuss the relative merits of different
approaches to intentional weight loss: lifestyle changes, bariatric
surgery, and pharmacotherapy. It is important to remember that
some medications used to treat T2DM may induce weight gain
(insulin, sulfonylureas, glinides, thiazolidinediones), while others are
reported to be weight neutral (DPP-4 inhibitors, acarbose, miglitol,
bromocriptine) (Bray & Ryan, 2012). There are also a few antidiabetic
medications that may lead to a modest degree of weight loss
(metformin, pramlintide, exenatide, liraglutide) (Bray & Ryan,
2012). These effects should be considered when determining
treatment options for obese patients with T2DM.ian et al., 2003; Whelton et al., 2002). Figure adapted from Whelton et al., 2002.
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Lifestyle changes, involving modiﬁcation of diet, physical activity,
and behavior, are the initial approaches to weight-loss therapy
recommended by the National Heart, Lung, and Blood Institute
(NHLBI) (National Heart, Lung, & Blood Institute. The Clinical
Guidelines on the Identiﬁcation, 1998). The NHLBI guidelines state
that an initial weight loss of 10% of body weight achieved over 6
months, at a rate of 1 to 2 pounds per week, is an appropriate target to
decrease the severity of obesity-related risk factors (National Heart,
Lung, & Blood Institute. The Clinical Guidelines on the Identiﬁcation,
1998). The ADA also recommends weight loss of 7% or more for all
overweight or obese individuals who have or are at risk of developing
T2DM, citing caloric reduction, physical activity, and behavior
modiﬁcation as important elements in aiding and maintaining weight
loss (American Diabetes Association, 2012).
In the Look AHEAD (Action for Health in Diabetes) study, weight
loss of 8.6% with intensive lifestyle intervention (Table 1) was
associated with signiﬁcant improvements in CVD risk factors in
5145 overweight/obese participants with T2DM (Table 2) (Look
AHEAD Research Group et al., 2007). When stratifying these patients
by degree of weight loss, those achieving weight loss of 5% to b10%
experienced signiﬁcant improvements in CVD risk factors (Wing et al.,
2011) compared with participants whose weight remained stable.
Speciﬁcally, weight loss of 5% to 10% led to a 0.5% reduction in HbA1c, a
5 mmHg decrease in SBP and diastolic BP (DBP), a 5mg/dL increase in
HDL-cholesterol, and a 40mg/dL decrease in triglycerides (Wing et al.,
2011). For those who lost 10% to 15% of their body weight, the odds of
achieving clinically signiﬁcant improvements in most risk factors
were even greater (Wing et al., 2011). In the longer term, intensive
lifestyle intervention participants had modest weight loss (4.7% at 4
years), decreased sleep apnea, increased quality of life, and improved
CVD risk factors, while requiring fewer medications than the usual
care group (Look AHEAD Research Group &Wing, 2010). However, in
September 2012, an interim analysis found a lower than expected rate
of cardiovascular events in all participants with no signiﬁcant
difference between treatment arms, resulting in the Look AHEAD
study being ended prematurely (National Institutes of Health, 2012).
Weight loss through lifestyle changes alone is often difﬁcult to
implement and maintain (Barte et al., 2010; UKPDS Group, 1990),
with almost half of patients failing to maintain ≥75% of their initial
weight loss over 52 weeks (Wadden et al., 2010). Therefore, medical
interventions, such as surgery or pharmacotherapy, may be a
necessary adjunct in some patients.
3.2. Bariatric surgery
Bariatric surgery is recommended for consideration in adults with
body mass index (BMI) >35 kg/m2 and T2DM, especially if the T2DM
or associated comorbidities are difﬁcult to control with lifestyle and
pharmacologic therapy (American Diabetes Association, 2012).
Surgery can be a highly effective option for weight and comorbidity
reduction, providing medically signiﬁcant weight loss that is
sustained for more than 5 years in most patients (National Heart,
Lung, & Blood Institute. The Clinical Guidelines on the Identiﬁcation,
1998). Bariatric surgery has been shown to improve pancreatic β-cell
function (Hofsø et al., 2011) and may reduce the need for medication
in obese patients with T2DM and lead to remission of T2DM and
hypertension in some cases (Tables 1 and 2) (Cunneen, 2008; Kadera
et al., 2009).
The Swedish Obese Subjects (SOS) study, an ongoing, nonrandom-
ized, prospective, controlled study, demonstrated that the risk of
cardiovascular death and cardiovascular events, as assessed in 4047
obese subjects (of whom 2010 underwent bariatric surgery and
2037 received conventional treatment), was reduced in those who
received bariatric surgery compared with conventional treatment(Tables 1 and 2) (Sjöström et al., 2012). It was found that the beneﬁt
of bariatric surgery with respect to cardiovascular events was not
related to baseline BMI (P = .58), but was signiﬁcantly associated
with baseline plasma insulin (P b .001), with increasing baseline
insulin levels related to increasing treatment beneﬁt, suggesting that
insulin resistance, as opposed to general adiposity measured as BMI,
may be the driver for the increase in cardiovascular risk (Sjöström
et al., 2012).
Prevention of T2DM was assessed in a subanalysis of patients in
the SOS study without T2DM at baseline (1658 patients who
underwent bariatric surgery and a matched control group of 1771)
(Carlsson et al., 2012). During the follow-up period (up to 15 years),
110 participants in the bariatric-surgery group and 392 in the
control group developed T2DM, corresponding to incidence rates of
6.8 vs 28.4 cases per 1000 person-years, respectively (adjusted hazard
ratio with bariatric surgery, 0.17; 95% conﬁdence interval (CI),
0.13–0.21; P b .001), suggesting that bariatric surgery is an effective
adjunct to usual care in the prevention of T2DM in obese patients
(Carlsson et al., 2012).
Patients who have undergone bariatric surgery, however, need
lifelong lifestyle support and medical monitoring (American Diabetes
Association, 2012). It is also important to note that the presence of
T2DM is strongly associated with increased morbidity and mortality
following bariatric surgery, possibly related to complications, such as
impaired wound healing (Keidar, 2011). Therefore, less-invasive
methods of inducing weight loss in obese patients with T2DM should
also be considered.
3.3. Current weight-loss pharmacotherapies
In recognition of the beneﬁts of weight loss in reducing the need
for medication and the risk of long-term complications, attention is
now beginning to focus on the use of weight-loss medications in
obese patients with T2DM. Four medications, benzphetamine,
diethylpropion, phendimetrazine, and phentermine, are approved
for the short-term treatment of obesity (Bray & Ryan, 2012). Although
longer term weight loss data on phentermine and related changes in
BP and heart rate have been published, it is not approved in the United
States for use beyond a few weeks and is not approved in Europe
(Hendricks, Greenway, Westman, & Gupta, 2011). In addition,
pharmacotherapies for chronic weight management in adults are
now available, including orlistat and 2 pharmaceuticals recently
approved by the US FDA, lorcaserin and PHEN/TPM ER.
3.3.1. Orlistat
Orlistat (XENICAL, 2012), a weight-loss medication approved for
long-term treatment of obesity, is a gastrointestinal lipase inhibitor
that reduces the absorption of dietary fat. It has been shown in a large,
4-year, double-blind prospective study to result in modest weight
loss (5.8 kg vs 3.0 kg for orlistat vs placebo; intent-to-treat population
with last observation carried forward [ITT-LOCF]), a reduction in the
progression to T2DM compared with placebo (P = .0032), and
improvement in cardiometabolic risk factors (XENDOS, Table 1)
(Torgerson, Hauptman, Boldrin, & Sjöström, 2004). One- and 2-year
studies have also shown signiﬁcant improvements in lipid proﬁles,
glycemic control, and BP (Table 2) (Rössner, Sjöström, Noack,
Meinders, & Noseda, 2000; Torgerson et al., 2004). A recent systematic
review and meta-analysis to evaluate the effect of weight-loss
pharmacotherapies on cardiometabolic risk found that, along with a
reduction in weight of 2.4 kg (95% CI: –3.34 to –1.45), orlistat
improved several cardiometabolic parameters, including lipid proﬁle,
BP, and fasting glucose (Zhou et al., 2012).
3.3.1.1. Adverse events. During the XENDOS study, the most common
adverse events with orlistat were gastrointestinal, including ﬂatus
with discharge, oily spotting, and fecal urgency; these were mild to
Table 1
Effects of weight-loss treatment options on body weight.
Study Trial design Weight loss
Intensive lifestyle intervention
Look AHEAD (Action for Health in Diabetes)
(Look AHEAD Research Group et al., 2007)
• 1-year, multicenter RCT of 5145 overweight/obese patients
with T2DM
Mean change at year 1
• Randomized to ILI vs DSE
• 8.6% (ILI) vs 0.7% (DSE) (P b .0001 vs ILI)
Bariatric surgery
(Kadera et al., 2009) • Retrospective analysis of 71 insulin-dependent T2DM
patients undergoing RYGB from 2000 to 2006
Mean percentage of EWL at year 1
• RYGB: 59.9%
SAGB vs LB (Cunneen, 2008) • Meta-analysis of 129 studies (n = 28,980 patients) from
1998 to 2006
Mean percentage of EWL at year 3
• Randomized to SAGB (n = 4273) or LB (n = 24,707)
• SAGB: 56.4%
• LB: 50.2%
MOBIL (Morbid Obesity treatment, Bariatric
Surgery vs ILI) Study (Hofsø et al., 2011)
• 1-year, ancillary study of 119 morbidly obese patients
without T2DM undergoing RYGB or ILI
Mean weight loss at year 1
• 29 normal-weight patients with NGT (control)
• RYGB: 30% (P b .001 vs ILI)
• ILI: 9%
Swedish Obese Subjects (SOS) study
(Sjöström et al., 2012)
• 4047 obese subjects, 2010 who underwent bariatric surgery
and 2037 who received conventional treatment
Mean change in body weight after 2, 10, 15,
and 20 years
• Median follow-up of 14.7 years • Surgery: 23%, 17%, 16%, and 18%
• Control: 0%, 1% gain, 1%, and 1%
Pharmacotherapies
Orlistat
Orlistat Obesity Study Group
(Rössner et al., 2000)
• 2-year, multicenter, randomized, double-blind,
placebo-controlled study of 783 overweight/obese subjects
Mean weight loss at year 1
• Randomized to PBO or orlistat (60 mg or 120 mg), TID
• Orlistat 60 mg: 8.6%
• Combined with a nutritionally balanced diet, which led to a
600-kcal daily energy deﬁcit and supplied 30% of energy as fat
• Orlistat 120 mg: 9.7%
• ITT
• PBO: 6.6%
(P b .001, orlistat 60 mg or 120 mg vs PBO)
Mean weight regain at year 2
• Orlistat 60 mg: 6.8%
• Orlistat 120 mg: 7.6%
• PBO: 4.5%
(P ≤ .005, orlistat 60 mg or 120 mg vs PBO)
XENDOS (XENical in the prevention of
diabetes in obese subjects)
(Torgerson et al., 2004)
• 4-year, double-blind, prospective study, of 3305 obese patients Mean weight loss at 4 years
• Randomized to lifestyle changes plus either orlistat 120 mg or
PBO, TID
• Orlistat: 5.8 kg (P b .001 vs PBO)
• ITT-LOCF
• PBO: 3.0 kg
(Zhou et al., 2012) • Systematic review and meta-analysis to assess cardiometabolic
effects (10 studies included orlistat; 1 study was 16 weeks,
5 studies were 1 year, 1 study was 1.5 years, 2 studies were
2 years, 1 study was 4 years)
Overall weight loss
• Orlistat: 2.39 kg (95% CI: –3.34 to –1.45)
Lorcaserin
BLOOM (Behavioral Modiﬁcation and
Lorcaserin for Overweight and
Obesity Management)
(Smith et al., 2010)
• 2-year, RCT of 3182 overweight/obese patients Mean weight loss at year 1
• Randomized to lorcaserin 10 mg BID (n = 1595) or PBO
(n = 1587)
• Lorcaserin 5.8% (P b .001 vs PBO)
• ITT-LOCF
• PBO: 2.2%
Subjects achieving ≥5% weight loss at year 1
• Lorcaserin 47.5% (P b .001 vs PBO)
• PBO: 20.3%
BLOSSOM (Behavioral modiﬁcation and
Lorcaserin Second Study)
(Fidler et al., 2011)
• 1-year, RCT of 4008 overweight/obese patients Mean weight loss at year 1
• Randomized to lorcaserin 10 mg QD (n = 801),
10 mg BID (n = 1602), PBO (n = 1601)
• Lorcaserin QD: 4.7%
• Modiﬁed ITT-LOCF
• Lorcaserin BID: 5.8%
• PBO: 2.8%
(P b .001 vs PBO, both comparisons)
Subjects achieving ≥5% weight loss at year 1
• Lorcaserin 10 mg BID: 47.2%
• Lorcaserin 10 mg QD: 40.2%
• PBO: 25.0%
(P b .001 vs PBO, both comparisons)
BLOOM-DM (O'Neil et al., 2012) • 1-year, RCT of 604 overweight/obese patients with T2DM Mean weight loss at year 1
• Randomized to lorcaserin 10 mg QD (n = 95), 10 mg BID
(n = 256), PBO (n = 252)
• Lorcaserin 10 mg BID: 4.5%
• Concomitant metformin, sulfonylurea, or both
• Lorcaserin 10 mg QD: 5.0%
• Modiﬁed ITT-LOCF
• PBO: 1.5%
(P b .001 lorcaserin vs PBO, both comparisons)
Subjects achieving ≥5% weight loss at year 1
• Lorcaserin 10 mg BID: 37.5%
• Lorcaserin 10 mg QD: 44.7%
• PBO: 16.1%
(P b .001 lorcaserin vs PBO, both comparisons)
(continued on next page)
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Table 1 (continued)
Study Trial design Weight loss
Phentermine/Topiramate ER
EQUIP (Allison et al., 2012) • 1-year, RCT, double-blind, PBO-controlled phase 3 which
evaluated 1267 severely obese adults (BMI ≥35); excluding
those with T2DM
LS mean weight loss at year 1
• Randomized to 3.75/23 (n = 241), 15/92 (n = 512), and
PBO (n = 514)
• 3.75/23: 5.1%
• ITT-LOCF
• 15/92: 10.9%
• PBO: 1.6%
(P b .0001 vs PBO, both comparisons)
Subjects achieving ≥5% weight loss year 1
• 3.75/23: 44.9%
• 15/92: 66.7%
• PBO: 17.3%
(P b .0001 vs PBO, both comparisons)
CONQUER (Gadde et al., 2011) • 1-year, RCT, double-blind, PBO-controlled phase 3 which
evaluated 2487 overweight and obese adults with
≥2 weight-related comorbidities including T2DM
LS mean weight loss at year 1
• Randomized to 7.5/46 (n = 498), 15/92 (n = 995), and
PBO (n = 994)
• ITT-LOCF
• 7.5/46: 7.8%
• 15/92: 9.8%
• PBO: 1.2%
(P b .0001 vs PBO, both comparisons)
Subjects achieving ≥5% weight loss year 1
• 7.5/46: 62%
• 15/92: 70%
• PBO: 21%
(P b .0001 vs PBO, both comparisons)
Naltrexone SR/bupropion SR
COR-I (Greenway et al., 2010) • 1-year, RCT, double-blind, PBO-controlled phase 3 which
evaluated 1742 overweight and obese adults
Mean weight loss at year 1
• Randomized to naltrexone SR 16 mg/bupropion SR
360 mg/day (n = 578), naltrexone SR 32 mg/bupropion SR
360 mg/day (n = 583), and PBO (n = 581)
• NB16: 5.0% (P b .0001 vs PBO)
• NB32: 6.1% (P b .0001 vs PBO)
• PBO: 1.3%
Subjects achieving ≥5% weight loss 1 year
• NB16: 39% (P b .0001 vs PBO)
• NB32: 48% (P b .0001 vs PBO)
• PBO: 16%
COR-II (Rubino et al., 2010) • 1-year, RCT, double-blind, PBO-controlled phase 3 which
evaluated 1496 overweight and obese adults
Mean weight loss at year 1
• Randomized to naltrexone SR 32 mg/bupropion SR
360 mg/day (n = 702), or PBO (n = 456)
• NB32: 6.4% (P b .001 vs PBO)
• Modiﬁed ITT-LOCF: subjects with ≥1 post-baseline
weight on study drug
• PBO: 1.2%
Subjects achieving ≥5% weight loss 1 year
• NB32: 50.5% (P b .001 vs PBO)
• PBO: 17.1%
COR-DM (Hollander et al., 2010) • 1-year, RCT, double-blind, PBO-controlled phase 3 which
evaluated 505 overweight and obese adults with T2DM
Mean weight loss at year 1
• Randomized to naltrexone SR 32 mg/bupropion SR
360 mg/day (n = 265), or PBO (n = 159)
• NB32: 5.0% (P b .001 vs PBO)
• Modiﬁed ITT-LOCF: subjects with ≥1 post-baseline weight
on study drug
• PBO: 1.8%
Subjects achieving ≥5% weight loss year 1
• NB32: 44.5% (P b .001 vs PBO)
• PBO: 18.9%
COR-BMOD (Wadden et al., 2011) • 1-year, RCT, double-blind, PBO-controlled phase 3 which
evaluated 793 overweight and obese adults
Mean weight loss at year 1
• Randomized to behavior modiﬁcations plus naltrexone SR
32 mg/bupropion SR 360 mg/day (n = 591), or PBO (n = 202)
• NB32: 9.3% (P b .001 vs PBO)
• Modiﬁed ITT-LOCF: subjects with ≥1 post-baseline weight on
study drug
• PBO: 5.1%
Subjects achieving ≥5% weight loss 1 year
• NB32: 66.4% (P b .001 vs PBO)
• PBO: 42.5%
Liraglutide
(Astrup et al., 2009) • Double-blind, placebo controlled, 20-week, phase 2 trial, with
open-label orlistat comparator of 564 obese adults
Mean change from randomization (after a
diet and placebo run-in period) to week 20:
• QD placebo (n = 98), QD liraglutide (1.2 mg [n = 95], 1.8 mg
[n = 90], 2.4 mg [n = 93], or 3.0 mg [n = 93]), or TID orlistat
120 mg (n = 95)
• Liraglutide: –4.8 kg to –7.2 kg (P ≤ .003 vs
PBO, all doses; P ≤ .003 vs orlistat, 2.4 mg and
3.0 mg doses)
• PBO: –2.8 kg
• Orlistat: –4.1 kg
RCT, randomized, controlled trial; ILI, intensive lifestyle intervention; DSE, Diabetes Support and Education; RYGB, Roux-en-Y gastric bypass; EWL, excess weight loss; SAGB,
Swedish Adjustable Gastric Bypass; LB, Lap-Band; NGT, normal glucose tolerance; NB, naltrexone/bupropion; PBO, placebo
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Signiﬁcant decreases in fat-soluble vitamins (A, D, E, K1) in the orlistat
group occurredwhen comparedwith placebo (Torgerson et al., 2004);
however, the mean level of each vitamin assessed was within the
reference range during the 4-year study. Subjects receiving orlistat are
instructed to take vitamin supplements ≥2 hours before or after their
evening dose (XENICAL 2012).3.3.2. Lorcaserin
In 2012, the FDA approved the weight-loss drug lorcaserin, a
selective serotonin 2C receptor agonist that acts centrally to promote
weight loss by reducing food intake and promoting satiety (BELVIQ
2012). The exact mechanism of action is not known. Because
lorcaserin acts on serotonergic receptors, there is the potential for
serotonin syndrome, which manifests in autonomic, cognitive, and
Table 2
Effects of weight-loss treatment options on cardiometabolic risk factors.
Study Cardiometabolic risk factors
Intensive lifestyle intervention
Look AHEAD (Action for Health in Diabetes) (Look AHEAD
Research Group et al., 2007)
Mean change from baseline to 1 year (for ISI vs DSE)
• HbA1c decreased (P b .001)
• FG decreased (P b .001)
• SBP/DBP decreased (P b .001)
• HDL-C decreased (P b .001)
Triglycerides decreased (P b .001)
Bariatric surgery
(Kadera et al., 2009) • All patients achieved some improvement in insulin resistance as per reductions in HbA1c and reduction in
antidiabetic medication use (number and/or dose)
• 35/71 (49%) patients with insulin-dependent T2DM experienced remission (remission was deﬁned as an
HbA1c level b7.0% after the patient had not been taking any antidiabetic medications)
SAGB vs LB (Cunneen, 2008) • Improvements in hypertension, dyslipidemia, and T2DM in both arms (meta-analysis)
MOBIL (Morbid Obesity treatment, Bariatric Surgery vs ILI) Study
(Hofsø et al., 2011)
• Signiﬁcantly greater improvements in β-cell function with RYGB vs ILI (assessed using oral glucose
tolerance tests)
Swedish Obese Subjects (SOS) study (Sjöström et al., 2012) • Long-term follow-up showed reduced incidence of cardiovascular death (P = .002 vs control) and
cardiovascular events (P b .001 vs control) in those who received bariatric surgery compared with
conventional treatment
Pharmacotherapies
Orlistat
(Rössner et al., 2000) Changes from baseline to year 1 (for orlistat vs PBO)
• LDL-C decreased (P b .001, orlistat 60 mg or 120 mg vs PBO)
• SBP changes similar
• DBP decreased with orlistat 120 mg vs PBO (P b .05, orlistat 120 mg vs PBO)
• FG decreased (P b .05, orlistat 60 mg or 120 mg vs PBO)
• FI decreased
XENDOS (XENical in the prevention of diabetes in obese subjects)
(Torgerson et al., 2004)
Effects from baseline to year 4 (for orlistat vs PBO)
• Reduced progression to T2DMa from baseline to year 4 (P = .0032 vs PBO)
• SBP decreased (P b .01)
• DBP decreased (P b .01)
• LDL-C decreased (P b .01)
• FG decreased (P b .01)
(Zhou et al., 2012) Effects from baseline to study end (meta-analysis; for orlistat vs PBO)
• Total cholesterol decreased (95% CI: –0.36 to –0.17)
• LDL-C decreased (95% CI: –0.30 to –0.12)
• FG decreased (95% CI: –0.20 to –0.04)
• SBP decreased (95% CI: –3.30 to –0.40)
• DBP decreased (95% CI: –2.39 to –0.58)
Lorcaserin
BLOOM (Behavioral Modiﬁcation and Lorcaserin for Overweight
and Obesity Management) (Smith et al., 2010)
Changes from baseline to year 1 (ITT-LOCF; for lorcaserin BID vs PBO)
• HbA1c decreased (P b .001)
• FG decreased (P b .001)
• SBP/DBP decreased (P b .05)
• HDL-C increased (not signiﬁcant)
• Triglycerides decreased (P b .001)
BLOSSOM (Behavioral modiﬁcation and Lorcaserin Second Study)
(Fidler et al., 2011)
Changes from baseline to year 1 (mITT-LOCF)
• SBP/DBP decreased with lorcaserin BID vs PBO (not signiﬁcant)
• HDL-C increased with lorcaserin QD and BID vs PBO (P b .05)
• Triglycerides decreased with lorcaserin QD and BID vs PBO (P b .05)
BLOOM-DM (O'Neil et al., 2012) Changes from baseline to year 1 (mITT-LOCF)
• HbA1c decreased with lorcaserin QD and BID vs PBO (P b .001)
• FG decreased with lorcaserin QD and BID vs PBO (P b .05)
• SBP/DBP not improved with lorcaserin vs PBO
• HDL-C increase with lorcaserin QD and BID vs PBO (P = .005 vs PBO for lorcaserin BID)
• Triglycerides decreased with lorcaserin QD and BID vs PBO
Phentermine/Topiramate ER
EQUIP (Allison et al., 2012) Changes from baseline to year 1 (ITT-LOCF; PHEN/TPM ER vs PBO)
• FG decreased (P b .0001 vs PBO with 15/92)
• SBP/DBP decreased (P b .05)
• LDL-C decreased (P = .0157 vs PBO with 15/92)
• HDL-C increased (P = .0005 vs PBO for 15/92)
• Triglycerides decreased (P b .0001 vs PBO with 15/92)
CONQUER (Gadde et al., 2011; Garvey et al., 2010) Changes from baseline to year 1 in the overall population (ITT-LOCF; PHEN/TPM ER vs PBO)
• FG decreased (P b .01)
• HbA1c decreased (P b .0001)
• FI decreased (P b .001)
• SBP/DBP decreased (P b .01 vs PBO for 15/92)
• LDL-C decreased (P = .0069 vs PBO for 15/92)
• HDL-C increased (P b .0001)
• Triglycerides decreased (P b .0001)
Changes from baseline to year 1 in subjects with T2DM (ITT-LOCF; PHEN/TPM ER vs PBO)
• FG decreased (not signiﬁcant)
• HbA1c decreased (P b .05)
(continued on next page)
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Table 2 (continued)
Study Cardiometabolic risk factors
Naltrexone SR/bupropion SR (investigational, not approved for weight loss)
COR-I (Greenway et al., 2010; Makowski et al., 2011) Changes from baseline to year 1 (for NB16/NB32 vs PBO)
• FG decreased (P b .05 vs PBO for NB32)
• FI decreased (P = .0007 vs PBO for NB32)
• SBP/DBP decreased less than with PBO (P b .05)
• HDL-C increased (P b .0001)
• Triglycerides decreased (P b .05)
COR-II (Makowski et al., 2011; Rubino et al., 2010) Changes from baseline to year 1 (mITT-LOCF; NB32 vs PBO)
• FI decreased (P b .001)
• LDL decreased (P b .05)
• HDL-C increased (P b .001)
• Triglycerides decreased (P b .001)
• SBP/DBP decreased less than with PBO
COR-DM (Hollander et al., 2010; Makowski et al., 2011) Changes from baseline to year 1 (mITT-LOCF; NB32 vs PBO)
• HbA1c decreased (P b .001)
• HDL-C increased (P b .001)
• Triglycerides decreased (P b .05)
• SBP/DBP decreased less than with PBO
COR-BMOD (Makowski et al., 2011; Wadden et al., 2011) Changes from baseline to year 1 (mITT-LOCF; NB32 vs PBO)
• FI decreased (P b .05)
• HDL-C increased (P b .001)
• Triglycerides decreased (P b .05)
• SBP/DBP decreased less than with PBO
Liraglutide (not approved for weight loss)
(Astrup et al., 2009) Mean change from randomization (after a diet and PBO run-in period) to week 20:
• SBP/DBP decreased with liraglutide vs PBO (not signiﬁcant)
• Pulse rate increased by 4 bpm vs PBO or orlistat
ILI, intensive lifestyle intervention; DSE, Diabetes Support and Education; FG, fasting glucose; SAGB, Swedish Adjustable Gastric Bypass; LB, Lap-Band; RYGB, Roux-en-Y Gastric
Bypass; PBO, placebo; FI, fasting insulin; NB, naltrexone/bupropion.
a A 75-g oral glucose tolerance test (OGTT) was performed at baseline and then at every 6months. Diagnosis of T2DMwas based on a single 2-h whole blood glucose measure≥10
mmol/L. After the ﬁrst 6months of the study, by a protocol amendment, patients with a diabetic OGTT underwent a repeat OGTTwithin 4weeks. A repeat positive test was based on a
2-h whole blood glucose ≥10 mmol/L, a whole blood fasting glucose ≥6.7 mmol/L, or 2 consecutive fasting whole blood glucose measurements ≥6.7 mmol/L.
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caution should be employed when lorcaserin is used in combination
with other serotonergically acting drugs, including, but not limited
to, selective serotonin-norepinephrine reuptake inhibitors, selective
serotonin reuptake inhibitors, triptans, and monoamine oxidase
inhibitors (BELVIQ 2012).
Lorcaserin is recommended to be administered at a dose of 10 mg
orally BID in conjunction with lifestyle intervention including a
reduced-calorie diet and increased physical activity. After 12 weeks,
therapy should be evaluated, and if the patient has not lost ≥5% of
baseline body weight, lorcaserin therapy should be discontinued
(BELVIQ 2012).
The efﬁcacy and safety of lorcaserin were evaluated in 3 separate
randomized, double-blind, placebo-controlled phase 3 trials. In the 2-
year Behavioral Modiﬁcation and Lorcaserin for Overweight and
Obesity Management (BLOOM) trial, 3182 subjects with a BMI≥30 to
≤45 kg/m2 or BMI ≥27 to ≤45 kg/m2 and ≥1 weight-related
comorbidity were randomized to receive placebo BID or lorcaserin
10 mg BID (Smith et al., 2010). The primary efﬁcacy end points
evaluated percent weight loss at 1 year (ITT-LOCF) and weight
maintenance through 2 years in subjects achieving at least 5% weight
loss at 1 year. The 1-year Behavioral modiﬁcation and Lorcaserin
Second Study for Obesity Management (BLOSSOM) randomized
4008 subjects with a BMI ≥30 to ≤45 kg/m2 or BMI ≥27 to
≤29.9 kg/m2 and ≥1 weight-related comorbidity to placebo,
lorcaserin 10 mg QD, or lorcaserin 10 mg BID (Fidler et al.,
2011). In BLOOM-DM, a 1-year trial, 604 overweight or obese
subjects (BMI ≥27 to ≤45 kg/m2) with T2DM treated with
metformin, a sulfonylurea, or both were randomized to placebo,
lorcaserin 10 mg QD, or lorcaserin 10 mg BID (O'Neil et al.,
2012). Both BLOSSOM and BLOOM-DM efﬁcacy analyses used a
modiﬁed ITT population with LOCF (mITT-LOCF) imputation for
missing data, including all patients who took ≥1 dose of study
drug and had ≥1 post-baseline body weight recorded. All
subjects were managed to standard of care for their respectivecomorbidities, including T2DM, and received dietary and lifestyle
counseling.
3.3.2.1. Weight loss. In the BLOOM trial, subjects receiving lorcaserin
experienced signiﬁcant weight loss vs placebo after 1 year (P b .001 vs
placebo; Table 1) (Smith et al., 2010). Additionally, more subjects in
the lorcaserin group than the placebo group achieved≥5%weight loss
(P b .001 vs placebo) (Smith et al., 2010). In subjects who continued
receiving lorcaserin during the second year, mean body weight was
lower than in those receiving placebo for 2 years and those receiving
lorcaserin in year 1 and placebo in year 2. However, although
remaining below baseline, weight steadily increased after week 52 in
patients who continued to receive lorcaserin for a second year
(Fig. 2A). In the BLOSSOM trial, lorcaserin QD and BID led to signiﬁcant
least-squares (LS) mean percent weight loss compared with placebo
(P b .01 vs placebo; mITT-LOCF; Table 1) (Fidler et al., 2011). Similar
to the BLOOM study, signiﬁcantly more subjects receiving lorcaserin
10 mg QD and BID in the BLOSSOM trial achieved ≥5% weight loss vs
placebo (P b .0001 vs placebo;mITT-LOCF) (Fidler et al., 2011). After 1
year of treatment in BLOOM-DM, subjects receiving lorcaserin
demonstrated signiﬁcant improvements in LS mean weight change
with lorcaserin 10 mg QD and BID, as well as with placebo (P b .001
for both vs placebo; Table 1; Fig. 2B)(O'Neil et al., 2012). Likewise,
more subjects achieved ≥5% weight loss with lorcaserin BID or
lorcaserin QD (P b .001 vs placebo; mITT-LOCF) (O'Neil et al., 2012).
In a phase 2b trial of 469 obese subjects, 31.2% of subjects completing
12 weeks of lorcaserin 10 mg BID treatment experienced weight loss
of ≥5%, which the lorcaserin label deﬁnes as responders (BELVIQ
2012; Smith et al., 2009).
3.3.2.2. Cardiometabolic parameters. In the BLOOM trial, glycemic
parameters (HbA1c, fasting glucose, and fasting insulin) were
improved when compared with placebo (Table 2); however, glucose
and insulin tended to increase over year 2 as body weight increased
(data not shown) (Smith et al., 2010). Similarly, lipid parameters
Fig. 2. (A)Weight loss over 2 years with lorcaserin (ITT-LOCF; BLOOM), (B) mean percent weight loss with lorcaserin in subjects with T2DM from baseline to 52 weeks (mITT-LOCF;
BLOOM-DM), (C) weight loss over 2 years with PHEN/TPM ER (SEQUEL), (D) least-squares mean percent weight loss with PHEN/TPM ER in subjects with T2DM from baseline to 56
weeks (ITT-LOCF; CONQUER) (Garvey et al., 2010; Garvey et al., 2012; O'Neil et al., 2012; Smith et al., 2010). Figures adapted from (Garvey et al., 2010; Garvey et al., 2012; O'Neil
et al., 2012; Smith et al., 2010).
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when compared with placebo at year 1 (Table 2), but these
parameters were increased to levels comparable with those observed
in the placebo group by year 2 (Smith et al., 2010). BP was also
improved at year 1 (Table 2), with these changes maintained through
year 2 (Smith et al., 2010). Subjects without T2DM in the BLOSSOM
trial receiving lorcaserin did not experience signiﬁcant changes in
HbA1c, LDL-cholesterol, SBP, or DBP vs placebo after 1 year (Table 2)
(Fidler et al., 2011). However, both HDL-cholesterol and triglycerides
were reduced vs placebo in lorcaserin-treated patients (P b .05;
Table 2) (Fidler et al., 2011). In the BLOOM-DM study, subjects with
T2DM receiving lorcaserin QD or BID experienced improvements in
HbA1c (P b .001) and fasting glucose (P b .001 vs placebo; Table 2)
(O'Neil et al., 2012). However, no statistical differences were seen
between groups in terms of SBP or DBP (Table 2) (O'Neil et al., 2012).
3.3.2.3. Adverse events. During the BLOOM and BLOSSOM trials, the
most common adverse events were upper respiratory infections,
headache, dizziness, nasopharyngitis, and nausea (Fidler et al., 2011;
Smith et al., 2010). The rates of FDA-deﬁned valvulopathy after 1 year
were equivalent in all groups: 2.7% in the lorcaserin 10 mg BID group
vs 2.3% in the placebo group in the BLOOM study and 2.0%, 1.4%, and2.0% in the lorcaserin 10 mg BID, lorcaserin 10 mg QD, and placebo
arms, respectively, in the BLOSSOM study (Fidler et al., 2011; Smith
et al., 2010). As with the BLOOM and BLOSSOM trials, the most
common adverse events reported by subjects with T2DM in the
BLOOM-DM trial were headache, back pain, nasopharyngitis, and
nausea (O'Neil et al., 2012). At week 52 in the BLOOM-DM trial, 2.9%
and 2.5% of lorcaserin 10 mg BID and lorcaserin 10 mg QD T2DM
patients, respectively, reported new valvulopathy, but the rate in
placebo-treated patients with T2DM fell to 0.5%; these changes were
not signiﬁcant (O'Neil et al., 2012). In addition, patient-reported
hypoglycemia occurred in 29.3% of subjects receiving lorcaserin 10mg
BID and 21.0% of subjects receiving placebo (BELVIQ 2012), with
symptomatic hypoglycemia occurring in 7.4% of subjects with T2DM
receiving lorcaserin 10 mg BID, 10.5% receiving lorcaserin 10 mg QD,
and 6.3% receiving placebo; both were more frequent in subjects
receiving sulfonylureas (O'Neil et al., 2012).
3.3.3. Phentermine and topiramate extended-release
In 2012, PHEN/TPM ER was approved by the FDA for chronic
weight management to be taken QD in the morning. It is a
combination formulation with multiple mechanisms of action
(QSYMIA 2012). Phentermine hydrochloride, a sympathomimetic
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catecholamines in the hypothalamus, resulting in reduced appetite
and decreased food consumption (QSYMIA 2012). Topiramate, a
sulfamate-substitutedmonosaccharide antiepileptic drug, may lead to
weight loss through its effects on both appetite suppression and
satiety enhancement, induced by a combination of pharmacologic
effects, including augmenting the activity of the neurotransmitter
gamma-aminobutyrate, modulation of voltage-gated ion channels,
inhibition of AMPA/kainite excitatory glutamate receptors, or inhibi-
tion of carbonic anhydrase (QSYMIA 2012). The topiramate compo-
nent of PHEN/TPM ER is an extended-release formulation, which
allows for QD dosing and a lower Cmax than the immediate-release
formulation of topiramate and improves tolerability. There is a
teratogenic risk associated with topiramate therapy; therefore,
PHEN/TPM ER was initially available only through mail order, but is
expanding to retail pharmacies in summer 2013 under the Risk
Evaluation and Mitigation Strategy (REMS), which provides patient
information with each prescription or reﬁll (QSYMIA 2012).
A treatment algorithm has been proposed to maximize patient
beneﬁt-risk. Treatment should startwith PHEN3.75mg/TPMER 23mg
(3.75/23) QD for 2weeks (14 days) and then increase to PHEN 7.5mg/
TPM ER 46 mg (7.5/46) QD for 12 weeks (QSYMIA 2012). Weight loss
should be evaluated after 12 weeks on the 7.5/46 dose, and if the
patient has not lost ≥3% of body weight, treatment should be
discontinued or the dose increased to PHEN 15 mg/TPM ER 92 mg
(15/92) in a 2-step process, increasing to PHEN 11.25 mg/TPM ER
69 mg QD for 2 weeks followed by 15/92 QD for 12 weeks. If after
12 additionalweeks of treatmentwith 15/92 a patient has not lost≥5%
of baseline bodyweight, treatment should be discontinued as directed.
The efﬁcacy and safety of PHEN/TPM ER were evaluated in two 1-
year, randomized, double-blind, placebo-controlled phase 3 trials. The
EQUIP study evaluated 1267 obese adults (BMI ≥35 kg/m2)
randomized to placebo, 3.75/23, or 15/92 (Allison et al., 2012). The
CONQUER study evaluated 2487 overweight and obese adults (BMI
≥27 kg/m2 and ≤45 kg/m2) with ≥2 weight-related comorbidities,
including T2DM and cardiovascular disease (Gadde et al., 2011).
Subjects were randomized to placebo, 7.5/46, or 15/92. After the
initial 56 weeks of treatment in CONQUER, 676 subjects at a subset of
sites continued into the SEQUEL extension study, which evaluated
subjects for an additional 52 weeks while maintaining their original
blinded randomization (Garvey et al., 2012). All subjects were
managed to standard of care for their respective comorbidities,
including T2DM, and received dietary and lifestyle counseling based
on the LEARN program (Brownell, 2000).3.3.3.1. Weight loss. In the EQUIP trial, use of PHEN/TPM ER led to
signiﬁcant weight loss over 56 weeks when compared with placebo,
and more subjects achieved weight loss of ≥5% at 1 year than did
those receiving placebo (P b .0001 vs placebo; ITT-LOCF; Table 1)
(Allison et al., 2012). After 1 year in the CONQUER study, LS mean
percent weight loss in the overall population was signiﬁcantly greater
than with placebo (P b .0001; ITT-LOCF; Table 1) (Gadde et al., 2011)
andwas sustained through 2 years in the SEQUEL trial (P b .0001; ITT-
LOCF; Table 1; Fig. 2C) (Garvey et al., 2012). In the CONQUER trial,
more subjects receiving PHEN/TPM ER achieved weight loss of≥5% at
1 year than did those receiving placebo (P b .0001 vs placebo; ITT-
LOCF; Table 1) (Gadde et al., 2011), and this was also maintained
through 2 years in the SEQUEL trial (P b .0001 vs placebo; ITT-LOCF;
Table 1) (Garvey et al., 2012). Similarly, those subjects who had T2DM
at baseline experienced signiﬁcant LS mean percent weight loss after
1 year of treatment (P b .0001 vs placebo; ITT-LOCF; Fig. 2D) (Gadde
et al., 2011; Garvey, Peterson, & Troupin, 2010). A pooled analysis of
clinical trial results found that 83.5% of subjects completing 12 weeks
of 7.5/46 treatment were responders (≥3% weight loss at 12 weeks),
as deﬁned in the label (Dvorak, Peterson, & Day, 2012; QSYMIA 2012).3.3.3.2. Cardiometabolic parameters. The weight loss experienced by
subjects receiving PHEN/TPM ER was associated with improvements
in several cardiometabolic parameters. In EQUIP, obese subjects
experienced signiﬁcant improvements in fasting glucose, blood
pressure, and lipid parameters in the 15/92 arm at year 1 (P b .05 vs
placebo; ITT-LOCF; Table 2) (Allison et al., 2012). Additionally, in the
overall CONQUER population, signiﬁcant improvements vs placebo in
these parameters were also experienced at year 1 (Gadde et al., 2011).
As in the overall population, subjects with T2DM at baseline
receiving PHEN/TPM ER had greater improvements vs placebo in
glycemic parameters at 1 year in the CONQUER study (Table 2)
(Gadde et al., 2011). These improvements in glycemic parameters
were greater with PHEN/TPM ER than with placebo, and fewer of
these actively managed subjects receiving PHEN/TPM ER required an
increase in concomitant antidiabetic medications (Gadde et al., 2011):
12.1% of subjects with T2DM in the placebo group required a net
increase in antidiabetic medications, compared with only 1.5% and
0.6% of subjects in the 7.5/46 and 15/92 groups, respectively (Garvey
et al., 2010).
3.3.3.3. Adverse events. In the EQUIP study, the most common adverse
events were paraesthesia, dry mouth, constipation, headache,
dysgeusia, and insomnia (Allison et al., 2012); in the CONQUER
study, dry mouth, paraesthesia, constipation, insomnia, dizziness, and
dysgeusia. Similarly, the types of adverse events occurring between
years 1 and 2 in the SEQUEL study were similar to those reported in
the overall CONQUER sample from baseline to year 1, although the
incidence of individual treatment-emergent adverse events was
markedly lower in the second year (weeks 56–108) (Garvey et al.,
2012). In EQUIP and CONQUER, there were small increases in mean
heart rate: EQUIP, –0.2, –0.3, and 1.2 bpm with placebo, 3.75/23, and
15/92, respectively (Allison et al., 2012); CONQUER, –0.1, 0.1, and 1.7
bpmwith placebo, 7.5/46, and 15/92, respectively (Gadde et al., 2011;
Garvey et al., 2012). However, mean BP was decreased with PHEN/
TPM ER treatment vs placebo and there were no adverse events
reported that were associated with changes in heart rate (Allison
et al., 2012; Gadde et al., 2011; Garvey et al., 2012).
3.4. Investigational weight-loss pharmacotherapies
3.4.1. Naltrexone sustained-release and bupropion sustained-release
An additional therapy under investigation for the treatment of
obesity is a combination of naltrexone sustained-release (SR) and
bupropion SR. The Contrave Obesity Research (COR) Program
consisted of four 1-year, phase 3 trials of overweight/obese patients:
COR-I (Greenway et al., 2010), COR-II (Rubino et al., 2010), and COR-
Behavioral Modiﬁcation (COR-BMOD) (Wadden et al., 2011), which
excluded participants with T2DM; and COR-Diabetes Mellitus
(CORDM) (Hollander et al., 2010), which included participants with
T2DM (Makowski, Gwinn, & Hurren, 2011). Participants in COR-I,
COR-II, and COR-DM received lifestyle counseling, including de-
creased energy consumption by 500 kcal/day and increased physical
activity, at baseline and every 12 weeks (Greenway et al., 2010; US
Food & Drug Administration, 2012). Alternatively, participants in the
COR-BMOD trial attended 90-minute multidisciplinary group visits
weekly for 16 weeks and monthly thereafter and were prescribed
1200 to 2000 kcal/day diets and encouraged to engage in physical
activity for 180 min/week for the ﬁrst 6 months, increasing to
360 min/week thereafter (Wadden et al., 2011).
In each of these trials, naltrexone SR/bupropion SR produced
greater weight loss and improvements in cardiometabolic parameters
when compared with placebo (Table 1) (Greenway et al., 2010;
Makowski et al., 2011; US Food & Drug Administration, 2012;Wadden
et al., 2011). In the CORDM study, among patients with T2DM using
oral or no antidiabetic medications, naltrexone SR/bupropion SR was
found to induce signiﬁcant weight loss and improvements in HbA1c
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HDL-cholesterol (Table 2) (Hollander et al., 2010; Makowski et al.,
2011; US Food & Drug Administration, 2012). In all trials, after 56
weeks of treatment, the placebo groups experienced greater de-
creases in SBP and DBP than did the naltrexone SR/bupropion SR
groups (Makowski et al., 2011; US Food & Drug Administration, 2012).
In the phase 3 trials, the most common adverse events were nausea,
constipation, headache, vomiting, and dizziness. Further, at 56 weeks,
heart rate was increased by an average of 0.3 bpmwith naltrexone SR/
bupropion SR vs –0.98 bpm with placebo (Makowski et al., 2011; US
Food & Drug Administration, 2012).
In January 2011, the FDA issued Orexigen, the manufacturer of
naltrexone SR/bupropion SR, a complete response letter in which a
cardiovascular outcomes trial (CVOT; The Light Study) was requested.
Orexigen initiated enrollment in the CVOT inMay 2012. The estimated
completion date of the CVOT is July 2017. Completion date will be
dependent on the time needed to accrue enough events to statistically
assess hazard ratios from an interim analysis. The primary outcome
measure will be time from treatment-period randomization to the
ﬁrst conﬁrmed occurrence of major adverse cardiovascular event
(MACE), with secondary end points including time from treatment-
period randomization to the ﬁrst conﬁrmed cardiovascular death,
myocardial infarction (fatal/nonfatal), stroke (fatal/nonfatal), and
nonfatal unstable angina requiring hospitalization (Cardiovascular
outcomes, 2012). Subjects will include overweight and obese (BMI
≥27 and ≤50 kg/m2) adults ≥45 years old who are at a high risk of
experiencing these events due to T2DM and/or other cardiovascular
risk factors; participants will be randomized to placebo or naltrexone
SR 32 mg/buproprion SR 360 mg/day.
3.4.2. Liraglutide
Liraglutide (Novo Nordisk A/S, Bagsvaerd, Denmark), a glucagon-
like peptide-1 analog, is currently approved for the treatment of
T2DM and has demonstrated weight-loss properties (Astrup et al.,
2009). In a double-blind, placebo controlled, 20-week, phase 2 trial,
with open-label orlistat comparator, 564 obese adults (≤65 years,
BMI ≥30 to ≤40 kg/m2) were randomized to placebo QD, liraglutide
QD (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg), or orlistat TID (120 mg). After
20 weeks, liraglutide use led to signiﬁcant weight loss vs placebo and
vs orlistat (P b .01; Table 1). Reductions in BP and increases in heart
rate of up to 4 bpmwere also observed (Table 2) (Astrup et al., 2009).
The most common adverse events were nausea and vomiting. Phase 3
studies in overweight and obese patients with comorbidities are
currently underway or completed but not reported in the literature;
primary end points include change in body weight, percentage of
patients achieving ≥5% or ≥10% weight loss, and proportion of
subjects progressing to T2DM (Clinicaltrials.gov, 2012).
4. Conclusion
As the rates of obesity and T2DM continue to increase, the need for
effective weight-loss strategies becomes more urgent. While lifestyle
interventions and bariatric surgery have been shown to reduce body
weight and improve risk factors related to T2DM and CVD, lifestyle
interventions alone are difﬁcult to maintain, and bariatric surgery,
which is available to a limited number of patients, can be associated
with greater risks. Currently available orlistat has demonstrated only
moderate weight loss, and adherence is limited by tolerability.
Lorcaserin and PHEN/TPM ER were recently approved by the FDA,
and clinical trials demonstrated both signiﬁcant, durable weight
loss compared with placebo and improvements in glycemic param-
eters and cardiometabolic risk factors in overweight/obese patients
with and without T2DM. Both lorcaserin and PHEN/TPM ER were
well-tolerated in clinical studies and will be followed for long-
term safety. These results suggest that lorcaserin or PHEN/TPM ER,
when used in conjunction with lifestyle modiﬁcations, may representa safe and effective therapy for the management of obesity in patients
with T2DM.
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